Literature DB >> 24088861

Clinical outcomes with rapid detection of methicillin-resistant and methicillin-susceptible Staphylococcus aureus isolates from routine blood cultures.

Nicole C Nicolsen1, Nicholas LeCroy, Nicholas Lecroy, Kevin Alby, Kelly E Martin, Jeffrey Laux, Feng-Chang Lin, Lindsay Daniels, David J Weber, Melissa B Miller.   

Abstract

Staphylococcus aureus is a common cause of bacteremia, with a substantial impact on morbidity and mortality. Because of increasing rates of methicillin-resistant Staphylococcus aureus, vancomycin has become the standard empirical therapy. However, beta-lactam antibiotics remain the best treatment choice for methicillin-susceptible strains. Placing patients quickly on the optimal therapy is one goal of antimicrobial stewardship. This retrospective, observational, single-center study compared 33 control patients utilizing only traditional full-susceptibility methodology to 22 case patients utilizing rapid methodology with CHROMagar medium to detect and differentiate methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains hours before full susceptibilities were reported. The time to targeted therapy was statistically significantly different between control patients (mean, 56.5 ± 13.6 h) and case patients (44.3 ± 17.9 h) (P = 0.006). Intensive care unit status, time of day results emerged, and patient age did not make a difference in time to targeted therapy, either singly or in combination. Neither length of stay (P = 0.61) nor survival (P = 1.0) was statistically significantly different. Rapid testing yielded a significant result, with a difference of 12.2 h to targeted therapy. However, there is still room for improvement, as the difference in time to susceptibility test result between the full traditional methodology and CHROMagar was even larger (26.5 h). This study supports the hypothesis that rapid testing plays a role in antimicrobial stewardship by getting patients on targeted therapy faster.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24088861      PMCID: PMC3838081          DOI: 10.1128/JCM.01667-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  9 in total

Review 1.  Rapid testing for methicillin-resistant Staphylococcus aureus: implications for antimicrobial stewardship.

Authors:  Krystina Geiger; Jack Brown
Journal:  Am J Health Syst Pharm       Date:  2013-02-15       Impact factor: 2.637

Review 2.  Predictors of mortality in Staphylococcus aureus Bacteremia.

Authors:  Sebastian J van Hal; Slade O Jensen; Vikram L Vaska; Björn A Espedido; David L Paterson; Iain B Gosbell
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

3.  Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).

Authors:  Douglas J Biedenbach; Gary J Moet; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2004-09       Impact factor: 2.803

Review 4.  Treatment of bacteraemia: meticillin-resistant Staphylococcus aureus (MRSA) to vancomycin-resistant S. aureus (VRSA).

Authors:  I M Gould
Journal:  Int J Antimicrob Agents       Date:  2013-05-08       Impact factor: 5.283

5.  Impact of a rapid peptide nucleic acid fluorescence in situ hybridization assay on treatment of Candida infections.

Authors:  Emily L Heil; Lindsay M Daniels; Dustin M Long; Kyle G Rodino; David J Weber; Melissa B Miller
Journal:  Am J Health Syst Pharm       Date:  2012-11-01       Impact factor: 2.637

6.  Outcome and attributable mortality in critically Ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

Authors:  Stijn I Blot; Koenraad H Vandewoude; Eric A Hoste; Francis A Colardyn
Journal:  Arch Intern Med       Date:  2002-10-28

7.  Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia.

Authors:  Marin L Schweizer; Jon P Furuno; Anthony D Harris; J Kristie Johnson; Michelle D Shardell; Jessina C McGregor; Kerri A Thom; Sara E Cosgrove; George Sakoulas; Eli N Perencevich
Journal:  BMC Infect Dis       Date:  2011-10-19       Impact factor: 3.090

8.  Shortened Time to Identify Staphylococcus Species from Blood Cultures and Methicillin Resistance Testing Using CHROMAgar.

Authors:  Shingo Chihara; Mary K Hayden; Eileen Minogue-Corbett; Kamaljit Singh
Journal:  Int J Microbiol       Date:  2009-01-11

9.  Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States.

Authors:  David Styers; Daniel J Sheehan; Patricia Hogan; Daniel F Sahm
Journal:  Ann Clin Microbiol Antimicrob       Date:  2006-02-09       Impact factor: 3.944

  9 in total
  4 in total

Review 1.  Rapid molecular diagnostic tests in patients with bacteremia: evaluation of their impact on decision making and clinical outcomes.

Authors:  K Z Vardakas; F I Anifantaki; K K Trigkidis; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-09-02       Impact factor: 3.267

2.  Efficacy of Ceftaroline against Methicillin-Susceptible Staphylococcus aureus Exhibiting the Cefazolin High-Inoculum Effect in a Rat Model of Endocarditis.

Authors:  Kavindra V Singh; Truc T Tran; Esteban C Nannini; Vincent H Tam; Cesar A Arias; Barbara E Murray
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

Review 3.  Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment.

Authors:  Ali Hassoun; Peter K Linden; Bruce Friedman
Journal:  Crit Care       Date:  2017-08-14       Impact factor: 9.097

4.  Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection.

Authors:  Vanesa Anton-Vazquez; Paul Hine; Sanjeev Krishna; Marty Chaplin; Timothy Planche
Journal:  Cochrane Database Syst Rev       Date:  2021-05-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.